POU5F1 and cancer: These two licensed drugs have the highest DGIdb interaction scores of the three compounds that interact with POU5F1/OCT4, inhibit a range of other cancer-relevant molecular targets and are also currently in trials as cancer therapeutics, making them attractive candidate drugs for further in vitro analysis for ES.